An expert physician provides an overview of the PROVE-HF trial and considers the practical implications for heart failure with reduced ejection fraction.
Scott D. Solomon, MD: I'll tell you a bit about several studies that we [at Brigham and Women’s Hospital] did that looked at the effect of sacubitril/valsartan in patients with heart failure with reduced ejection fraction on ventricular structure and function, as well as a number of other things, including natriuretic peptides and measures of quality of life.
We did 2 trials around the same time. The first was called PROVE-HF, and the other was called EVALUATE-HF, and they both enrolled patients with heart failure with reduced ejection fraction. In the PROVE-HF trial, we enrolled people who were not currently taking sacubitril/valsartan, but had heart failure with reduced injection fraction and were indicated for sacubitril/valsartan. They were switched from whatever drug they were previously on, presumably an ACE [angiotensin-converting enzyme] inhibitor or ARB [angiotensin 2 receptor blockers], to sacubitril/valsartan. They were then followed for 1 year, and the primary end point was a reduction in NT-proBNP [N-terminal pro-b-type natriuretic peptide], or natriuretic peptides. We also looked at the effect on cardiac structure and function, ventricular size and function, as well as measures of quality of life.
This was a single-arm trial, so there was no comparative group. The reason there was no comparative group is that we considered it unethical to randomize patients for more than a short period to a comparator because of the benefits that had been shown with sacubitril/valsartan in the PARADIGM-HF trial. We looked at patients over the course of the year, and they reduced their NT-proBNP quite significantly. That reduction was associated with a reduction in cardiac events: heart failure, hospitalizations, and death. We also found that they had attenuation of ventricular remodel. That is, their hearts, which started out on the larger side, became smaller, and their ejection fractions went up by a substantial amount. We believe that this therapy is working by reducing ventricular size and improving cardiac function.
We didn’t do this trial with a comparator, but we did the other study I mentioned: EVALUATE-HF. It was a 12-week study comparing sacubitril/valsartan and enalapril. It showed similar overall results and improvement in ventricular volumes, for example. Even over a short period of 12 weeks, we saw improvements in quality of life and reduction in natriuretic peptides. We put these 2 sets of data together, and we say, “There is pretty strong evidence now that this therapy is improving ventricular remodeling in patients with heart failure with reduced ejection fraction.”
Discharge Timing and Associations With Outcomes Following Heart Failure Hospitalization
October 9th 2025A retrospective multicenter study found that patients with heart failure discharged by noon had higher short- and long-term mortality and increased early readmission rates compared with afternoon discharges.
Read More
What It Takes to Improve Guideline-Based Heart Failure Care With Ty J. Gluckman, MD
August 5th 2025Explore innovative strategies to enhance heart failure treatment through guideline-directed medical therapy, remote monitoring, and artificial intelligence–driven solutions for better patient outcomes.
Listen
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Racial, Ethnic Disparities May Impact Age Differences at First Heart Failure Hospitalization
September 4th 2025Social determinants of health were associated with a younger age of first hospitalization for heart failure in Black and Hispanic patients when compared with Asian and White patients.
Read More